Liquidia Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparative figures are for FY2021. The filing was signed March 20, 2023. This is an annual report, not a separate Q4 filing.
Business context
Liquidia is a biopharmaceutical company focused on pulmonary hypertension. Its current revenue is primarily its profit share under an agreement with Sandoz to promote generic treprostinil injection. Its lead candidate, YUTREPIA, is a PRINT-engineered dry-powder treprostinil inhaler for pulmonary arterial hypertension (PAH). The FDA tentatively approved YUTREPIA for PAH in November 2021, but it cannot be marketed without final approval.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $15.9 million | $12.9 million |
| Cost of revenue | $2.9 million | $3.0 million |
| Research and development | $19.4 million | $20.5 million |
| General and administrative | $32.4 million | $23.1 million |
| Operating loss | $38.8 million | $33.8 million |
| Net loss | $41.0 million | $34.6 million |
| Net loss per share, basic and diluted | $0.67 | $0.70 |
| Cash used in operating activities | $28.6 million | $34.0 million |
| Cash and cash equivalents at year-end | $93.3 million | $57.5 million |
| Long-term debt at year-end | $19.9 million | $10.4 million |
Revenue less cost of revenue was approximately $13.1 million, or 82% of revenue; this is not a company-reported product gross margin. Current assets were $99.8 million and current liabilities were $8.8 million at year-end. Stockholders’ equity was $90.4 million, and accumulated deficit was $350.6 million. Net cash from financing activities was $65.0 million, mainly reflecting $54.5 million of net proceeds from an April 2022 public offering and debt financing.
Changes versus FY2021
- Revenue rose 24%, primarily reflecting higher unit sales of generic treprostinil. Liquidia’s profit share was 50% throughout 2022; in 2021 it fell from 80% to 50% after cumulative sales thresholds were reached.
- Net loss increased by $6.4 million. G&A grew 40%, including higher commercialization preparation costs and a $3.1 million increase in stock-based compensation, partly related to an option modification charge.
- R&D declined 5%; reported YUTREPIA-related R&D was $7.0 million versus $6.7 million.
- Operating cash outflow decreased by $5.4 million, while cash increased by $35.8 million, chiefly due to equity and debt financing rather than positive operating cash flow.
- Interest expense increased, and the company recorded a $1.0 million loss on extinguishment of debt associated with its January 2022 refinancing.
Outlook, risks and unusual items
- YUTREPIA approval and litigation: A September 2022 court judgment found United Therapeutics’ ’793 patent valid and infringed and barred final FDA approval before the patent’s 2027 expiration. Both parties appealed; Liquidia’s motion to stay enforcement was pending, and the PTAB had separately found the patent claims unpatentable, subject to appeal. The outcome and launch timing remained uncertain.
- Commercial opportunity: The FDA indicated that the existing clinical data could support pursuing a supplemental application for PH-ILD after relevant exclusivity for nebulized treprostinil expires in March 2024. United Therapeutics’ Tyvaso DPI was approved for PAH and PH-ILD in May 2022, creating competition.
- Liquidity and financing: In January 2023, HCR agreed to provide up to $100 million under a revenue-interest financing. $32.5 million was funded, of which $22.4 million repaid the SVB debt; remaining tranches are conditional or require mutual agreement. The financing includes revenue-linked payments, covenants, minimum cash requirements, and acceleration provisions. Management said year-end cash, excluding contingent HCR tranches and future YUTREPIA revenue, was expected to fund operations for at least 12 months from the filing date. The filing says additional capital would be needed if contingent HCR funding is unavailable or substantial YUTREPIA revenue is not generated by Q2 2024; inability to access further funding could raise substantial doubt about going concern as of the Q2 2023 financial-statement issuance date. The auditor’s report includes an emphasis-of-matter reference to the financing need.
- Treprostinil injection and pumps: A shortage of a critical CADD-MS 3 pump component restricted new patients from starting subcutaneous treatment. Smiths Medical support for that pump ends after January 1, 2025; support for the intravenous CADD Legacy pump is expected to end in 2028. Liquidia and Sandoz were pursuing component supply and a replacement pump with Mainbridge; FDA clearance and timing were not assured.
- Concentration and supply: Approximately 98% of FY2022 revenue came from the Sandoz Promotion Agreement, and one customer represented 99% of year-end accounts receivable. YUTREPIA relies on single suppliers for treprostinil API, its inhaler device, and encapsulation and packaging services.
- Other legal and financial matters: United Therapeutics’ trade-secret claims were in discovery after Liquidia’s dismissal motion was denied. A separate contract-damages trial in the RareGen litigation was scheduled for summer 2023; any proceeds to Liquidia PAH are subject to sharing and litigation-financing arrangements. Liquidia had held its cash at SVB at year-end; after SVB’s March 2023 closure, it reported moving substantially all cash to another financial institution.
- Management outlook: The company expects continuing losses and negative cash flows while it pursues development, regulatory approval, and commercialization. It provided no clear numerical revenue or earnings guidance in the supplied filing text.
Important facts for investors to verify
- Current status and likely timing of the ’793 patent appeals, the stay request, and the separate trade-secret litigation—and their implications for YUTREPIA’s final approval and launch.
- Availability and conditions of remaining HCR financing tranches, associated payment obligations and covenants, and updated liquidity/runway assumptions.
- Progress toward resolving CADD-MS 3 component constraints and developing, obtaining FDA clearance for, and supplying replacement pumps.
- Trends in Sandoz product sales, Liquidia’s profit-share economics, generic competition, and the concentration of revenue and receivables.
- YUTREPIA manufacturing readiness, sole-source supply continuity, and any regulatory or exclusivity developments affecting PAH or PH-ILD indications.